About Homie

Homie Razavi is the founder and managing director at the Center for Disease Analysis Foundation (CDAF), an organization working to accelerate hepatitis B and C elimination through development of verified epidemiological data, disease burden and economic impact modeling, intervention strategies, and access to affordable diagnostics and treatments.

Since 2008, Homie has led a team of epidemiologists and modellers to quantify epidemiology of hepatitis C virus (HCV) and forecast the future impact of HCV disease burden. They have analyzed HCV disease burden in over seventy countries and have helped countries develop national strategies. CDAF has been responsible for the development of a number of mathematical models currently used by countries to develop intervention strategies for HCV and HBV:
HCV disease progression
HCV transmission
HCV economic impact
HBV vertical transmission; economic impact
HBV disease progression/treatment; economic impact

In addition, CDAF has developed the Polaris Observatory, which collects and reports HCV, HBV and HDV epidemiology, disease burden and treatment rate annually. He has a broad background, which includes basic research, commercial development, portfolio management, and decision analysis. He is also a fellow in the Society of Decision Professionals.

This speaker will be presenting at the following session(s)

  • Strategic direction 4: financing for sustainability

    Golden Hall

    Day: 3 November

    Time: 09:00

    The first of two plenary sessions on strategic direction 4, which addresses the sustainable financing of hepatitis responses within a whole health systems approach.

    Chairs: Dr. Amanda Kgomotso Vilakazi Nhlapo, National Department of Health, South Africa and Dr. John Ward, US Centers for Disease Control and Prevention

    Presentations:

    • A strategic approach to financing hepatitis.
      Charles Gore, World Hepatitis Alliance
    • Costing, delivery and financing for hepatitis – the linkages.
      Dr. Jeremy Lauer, World Health Organization
    • Panel discussion: financing for hepatitis within a health systems approach.
      Moderator: Dr. Eduardo González Pier, Center for Global Development
      Dr. David Wilson, World Bank
      Dr. Jean Damascene Makuza, Rwanda Biomedical Center
      Dr. Jeremy Lauer, World Health Organization
      Dr. Homie Razavi, Center for Disease Analysis Foundation

      Dr. Cielo Yaneth Ríos-Hincapié, Ministry of Health and Social Protection, Colombia

    Session objective:

    • Discover how to approach hepatitis costing, budgeting and financing in a structured way.
    • Understand how the financing system must match the service delivery model and where there are opportunities for integration.
    • Learn how countries can best approach sustainable financing for hepatitis.
  • Different financing mechanisms for viral hepatitis programmes

    Golden Hall

    Day: 3 November

    Time: 11:00

    This session examines potential hepatitis financing mechanisms that will be required for countries to launch, accelerate and sustain public health responses to viral hepatitis.

    Chairs: Dr Adele Benzaken, Ministry of Health, Brazil and Dr. Philippe Duneton, Unitaid

    Presentations:

    • From economic analysis to financial dialogue.
      Dr. Homie Razavi, Center for Disease Analysis Foundation
    • A new Fund for Elimination of Viral Hepatitis: EndHEP2030.
      Wangsheng Li, Zeshan Foundation
    • Getting started with funding: catalytic initiatives.
      Taryn Barker, Clinton Health Access Initiative
    • Engaging Ministries of Finance.
      Eduardo González-Pier, Center for Global Development
    • Domestic funding.
    • Jeremy Lauer, World Health Organization, in conversation with Dr. Chinburen Jigjidsuren, Ministry of Health, Mongolia
    • Q & A session.

    Session objectives:

    • Understand the global investment case and its use in attracting donors.
    • Learn how to ensure the support of Ministries of Finance.
    • Understand how the public and private sector can be combined.
    • Discover how 3 countries have approached hepatitis financing.

  • Policy as a tool for HepC Elimination

    Matisse

    Day: 1 November

    Time: 17:30

    Hepatitis C virus (HCV) infection is considered a major Public Health threat in Europe.

    Hepatitis C virus (HCV) infection is considered a major Public Health threat in Europe. Hepatitis C is a chronic infectious disease with great impact on patients’ morbidity and mortality, with high risk of progression to cirrhosis and liver cancer. In Europe, it is estimated that only 25% of patients with hepatitis C are diagnosed (~14 million people); each year there are 27,000-29,000 newly diagnosed HCV cases in the EU/EEA. Evidence shows that, for some European countries, annual deaths from hepatitis c have quadrupled over the past 20 years. New treatments were recently discovered that cures hepatitis C in up to 97% of cases. This, alongside the devastating effects that the disease can have, means that the paradigm at the community level of hepatitis c treatment should now be elimination.

    Presentations:

    • From policy to action.
      Charles Gore, World Hepatitis Alliance
    • What matters to patients - HepCore.
      Prof. Jeffrey Lazarus, University of Copenhagen
    • Empowering advocates.
      Achim Kautz, Leberhilfe Projekt gUG
    • Modelling for policy change.
      Dr. Homie A. Razavi, Center for Disease Analysis Foundation
    • Brazil strategy and response to HCV.
      Evaldo Stanislau Affonso de Araújo, Hospital das Clínicas Faculdade de Medicina da Universidade de São Paulo
    • Let's End HepC Dashboard - assessing and comparing different Countries policies in real-time towards the elimination of HCV until 2030.
      Ricardo Baptista Leite, Member of the Portuguese Parliament and Católica University of Portugal